Evidence Level
Moderate Evidence
Mechanism of Action
Amylin receptor agonist. Amylin is co-secreted with insulin from beta cells. Slows gastric emptying, suppresses glucagon, and promotes satiety via hypothalamic pathways distinct from GLP-1.
Published Research Ranges & Study Context
Studies have administered: 0.3–4.5mg weekly in REDEFINE trials
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
REDEFINE-1 preliminary data: CagriSema combination showed up to 22.7% weight reduction at 68 weeks. Additive mechanism to semaglutide demonstrates incremental weight benefit.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
GI symptoms (nausea, constipation); injection site reactions common in trials
Available Configurations (SKU Reference)
CGL5
CGL10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Cagrilintide — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.